Case | HBS Case Collection | March 2014 (Revised December 2014)

Vision 2020: Takeda and the Vaccine Business

by John A. Quelch and Margaret L. Rodriguez


In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003 and chief executive in 2009. By 2013, Takeda was in the midst of implementing its new Vision 2020 plan, a strategic plan for the evolving global corporation, which included developing a global vaccine business.

Keywords: health care; global; NGO; public health; pharmaceutical industry; Japan; GSK; vaccine; supply chain; Market entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Health Industry; Pharmaceutical Industry;


Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)